Phoutsavanh Vongkhamxao has been declared the winner of Miss Grand Laos 2022 and will go on to represent Laos at the Miss Grand International 2022 pageant in Indonesia this October.
SSY announces 2022 interim results
Seize development opportunities; Enhance competitive strength
Result summary:
- Total revenue HK$3,405 million, representing a growth of 39.4%;
- Net profit HK$570 million, representing a growth of 106.8%;
- The Board resolved to pay interim dividend of HK$0.06 /share
HONG KONG SAR – Media OutReach – 29 August 2022 – SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the interim results of the Company for the six months ended 30 June 2022.
During the first half of 2022, the Group achieved a revenue of HK$3,405 million, representing an increase of 39.4% compared to corresponding period of last year (“1H2021”) with gross profit margin 57.0%, representing a decrease of 3.2 percentage points compared to 1H2021. The Group achieved a net profit of HK$570 million, representing an increase of 106.8% compared to 1H2021.
Faced with pressure from continuous impacts of the epidemic, shrinking market demands and supply shock, the Group seized the development opportunities arising from changes in the industrial landscape and policy support, and implemented a series of measures to improve quality and enhance efficiency of its main business segments including preparations, bulk pharmaceuticals and medical materials, so as to maintain good growth momentum. Focusing on the dual circulation of domestic and international markets development pattern, the Group concentrated its efforts on market development for dominant preparations and key types of preparation products, and explored the domestic and overseas markets for its bulk pharmaceuticals and medical materials products. The Group also proactively optimised its product mix and placed great emphasis on the marketing of new featured products, leading to a new growth in market shares and sales volume.
The Board of directors proposed to pay an interim dividend of HK$0.06 per share for year 2022, which increased by 20% as compared to 1H2021. The total amount of interim dividend this year to be paid is approximately HK$179 million.
Amidst the normality under epidemic, the domestic pharmaceutical market witnessed a stable rigid demand. The Group continued to increase the market shares of the intravenous infusion solution and continuously solidified its leading position in the market. During the first half year, the sales volume of infusion solutions reached 754 million bottles (bags), representing an increase of 19.3% compared to 1H2021. Revenue of infusion solutions reached HK$1,834 million, representing an increase of 20% compared to 1H2021. Ampoule products delivered a remarkable market performance and have become a new support for the development of the Group’s injection segment. During the first half year, the revenue of ampoule products was HK$511 million, representing an increase of 4.7% compared to 1H2021, which maintained a good growth momentum. Solid preparations business segment delivered a steady and positive sales performance. In line with the national and local centralised procurement policies, the Group made coordinated efforts to secure market supply of tender-awarded products to promote and expand the market of new products. During the first half year, the revenue reached HK$145 million, representing an increase of 71% compared to 1H2021. Bulk pharmaceuticals business achieved a boost in both production and sales. After continuous optimization of production process, the premium production capacities were realised rapidly. In particular, as a vertical integration, the Group acquired Cangzhou Lingang Youyi Chemical Co., Ltd. at the beginning of the year, significantly improving the coordination between upstream and downstream entities of the industrial chain. During the first half of the year, revenue of bulk pharmaceuticals reached HK$777 million, representing an increase of 214.6% as compared to 1H2021. The Group achieved a growth jump in production and sale of medical materials. In the first half of the year, revenue from external customers of the Group recorded HK$90.55 million, representing an increase of 12.5% compared to 1H2021.
By using market demands as the guide and adhering to the strategy of “combination of generic and innovative drugs”, the Group made continuous and coordinated efforts to push forward the research and development of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation. The Group kept solidifying and expanding its strength in the research and development of featured generic drugs. During the first half of the year, a total of 22 production approvals were obtained, including 14 types of infusion products and 8 types of bulk pharmaceuticals, with the number of approvals obtained exceeding that of the whole year of 2021. So far, a total of 26 product types with 35 specifications of the Group have passed or were regarded as passing the national consistency evaluations regarding the quality and efficacy of generic drugs. During the period, 124 products of various types were also submitted by the Group to the Center for Drug Evaluation of the National Medical Products Administration for approval, including 100 preparation products (including products for consistency evaluation) and 24 types of bulk pharmaceuticals. The Group achieved positive progress in the Phase 1 clinical trial of the Type I innovative drug NP-01 project, and were stepping up efforts in the preparation of application materials for Phase 1 clinical trial for the innovative drug including ADN- 9, aiming to apply within the year. In addition, the bioprocessing film project of Jiangsu Best New Medical Material Co. Ltd. with an annual production capacity of 20 million square meters has completed construction and was ready for production on July 2022, providing a solid foundation for overall improvement of market supply capacity.
Looking forward to the second half of 2022, economic situation may remain severe and complicated amidst the normality under global epidemic. The Group will actively seize development opportunities and will make effort to facilitate the dual circulation of domestic and international markets in order to secure preemptive opportunities for development. On the preparations business, the Group will have an in-depth and a better systematic analysis on national and local centralized procurement policies, and will seize the market opportunities arising from the eighth round of National Centralised Medicines Procurement, with an aim to expand the market share and influence of its products passing the consistency evaluation. On the bulk pharmaceuticals business, the Group will proactively facilitate the domestic and international markets, and make efforts to strengthen and expand its bulk pharmaceuticals business, aiming to make a greater contribution to the development of the Group. In terms of research and development, the research and development of specialised generic drugs remains the focus of the Group’s research and development work for the moment. Facing the increasingly intensified competition in the research and development of generic drugs, the Company will leverage on the cooperation mechanism with universities and scientific research institutes, and explore more high quality research projects. The Group will continue to push forward proactively the spinoff listing of bulk pharmaceuticals segment in the PRC. At the same time, the Group will proactively seek opportunities of acquisition and investment in the pharmaceutical industry in order to increase the return on investment.
Mr. Qu Jiguang, Chairman and CEO of SSY said, “Facing the risks and challenges in the post-pandemic era, the Group will seize new opportunities for development in the industry. We will maintain the resilience and vitality of innovative development, and strive for facilitating the quality development of the Group. We firmly believe that, by virtue of the scale, quality, management and brand advantages accumulated in the industry over the years and the continuous innovation momentum released by the Group, we will strive to create new high record again in year 2022 in terms of production, sales and profit, and will bring satisfactory returns to our investors with a stronger result of development.”
Hashtag: #SSY
The issuer is solely responsible for the content of this announcement.
About SSY Group Limited
SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, including finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, and its pharmaceutical products has leading position in the high-end hospital market in China.
Thailand Looks to Indian Weddings for New Tourism Revenue
Thailand is looking to Indian weddings as a new source of tourism following the loss of Chinese visitors this year.
Shopee Celebrates the Heart of Malaysia on E-Commerce
60% of Malaysian Consumers Buy Local Ahead of Merdeka Day
KUALA LUMPUR, MALAYSIA – Media OutReach – 29 August 2022 – 60% of Malaysian consumers are proactively supporting local sellers ahead of Merdeka Day with #ShopeeSapotLokal, at the live reveal of the platform’s largest marketplace study this year, Celebrating the Heart of Malaysia on E-Commerce*, ahead of the company’s 9.9 Super Shopping Day.

When 3,356 consumers were asked “Why do you think it is important to support local sellers?” during the month leading up to Merdeka Day, 30% endorsed the quality of Made-in-Malaysia goods that cater to their local preferences, 20% stated that they want to keep the economy running for patriotic reasons and 8% were sellers supporting other local sellers in the same boat. 42% preferred shopping local to get their items delivered faster.
Among these respondents, half of them (54%) are working full time, 18% are in-between jobs, 17% are senior citizens, 6% are stay-at-home parents and 5% are university students.
Shopee also examined what Malaysians valued about online shopping. Over 70% of consumers surveyed estimated that their everyday online shopping transactions resulted in savings of over 5% consistently. Economic uncertainty was the primary reason respondents valued every Ringgit saved, with 50% of buyers needing to reduce expenses in this environment, 14% not earning enough to cover essentials, 10% foreseeing major expenses in the coming months and 6% providing for multiple dependents.

“Interestingly, not all buyers prioritise discounts and vouchers exclusively. Seven in 10 Malaysians value peace of mind over lower price,” according to Kenneth Soh, Head of Marketing Campaigns at Shopee Malaysia.
Nine in 10 Malaysians still buy online despite the reopening of physical outlets because it is a learned and adopted habit. The majority value having ‘peace of mind’, with 40% enjoying the convenience of parcels delivered to their doorstep, 17% feeling safe with Shopee Guarantee, and 10% trusting reviews and pictures from other buyers.
For 49% of buyers, Shopee is the top-of-mind shopping destination for lifestyle products, including home decoration items, fashion pieces, and health and beauty products. Apart from that, 24% of buyers purchase living essentials (groceries and diapers) from Shopee, 16% look for tech devices (computers, mobile devices and TV) and the remaining 11% buy automobile parts or work and school supplies.
“When Malaysian consumers express their values through online shopping preferences this way, we truly understand why eight in 10 local sellers started their selling journey online with Shopee. We are humbled to discover that half of our local sellers surveyed say the income earned on our platform is crucial as it enables them to support their families,” said Soh.
The majority of local sellers began selling online with Shopee to overcome existing limitations on their earnings and participation in the economy: 24% because it is their only source of income, 5% can’t get a job, 18% need to supplement income and 24% feel the pressures of higher costs of living. 30% said they became Shopee sellers because of their passion for their business.
Save and Enjoy More with 9.9 Super Shopping Day
To enable Malaysians to stretch their Ringgit even more, Shopee’s 9.9 Super Shopping Day is currently happening till 9 September 2022. More value and joy await shoppers on top of Free Shipping with no minimum spend, daily 95% off deals and a chance to Shop & Win up to RM200,000**.
Malaysians can also look forward to Shopee Live daily exclusive vouchers, worth up to RM6 off with no minimum spend from any livestream on Shopee Live. The Live-exclusive vouchers refresh every day, so users should come back to Shopee livestream daily to claim and use the vouchers on 9.9 Super Shopping Day.
On top of that, users can also participate in the Shopee Live Buy & Win contest to stand a chance to win up to 100,000 Shopee Coins and Gold Bars. This is applicable for purchases made in any livestreams on Shopee Live from 26 August until 9 September.
To top it off, tune in to TV3, Shopee Live or Shopee’s YouTube channel at 9PM on 9 September to get your hands on the best TV deals in town from the Shopee 9.9 Super Show. Full of exciting performances, games and offers, Shopee will be treating Malaysians with Shopee Shake, Vouchers Drop and more during the show for an unforgettable 9.9 Super Shopping Day.
For more information about the Shopee 9.9 Super Shopping Day, visit https://shopee.com.my/m/99.
**Terms and conditions apply.
Notes:
1. Survey Methodology*
The 2022 “Celebrating the Heart of Malaysia on E-Commerce” survey was conducted by Shopee Marketplace, between 19 July to 17 August 2022. Voluntary feedback was obtained from 2,132 Malaysian sellers and 3,356 Malaysian buyers on the platform.
2. Shopee Malaysia held a virtual press conference on the marketplace survey – ‘Celebrating the Heart of Malaysia on E-Commerce’ on 25 August 2022. To view it in full, please contact pr.my@shopee.com.
Hashtag: #Shopee #MerdekaDay
About Shopee
Shopee is the leading e-commerce platform in Southeast Asia & Taiwan. Shopee promotes an inclusive and sustainable digital ecosystem by enabling businesses to digitalise and grow their online presence, helping more people access and benefit from digital services, and uplifting local communities.
Shopee offers an easy, secure, and engaging experience that is enjoyed by millions of people daily. Shopee is also a key contributor to the region’s digital economy with a firm commitment to helping homegrown brands and entrepreneurs succeed in e-commerce.
Shopee is part of Sea Limited (NYSE: SE), a leading global consumer internet company. Sea’s mission is to better the lives of consumers and small businesses with technology through its three core businesses: Shopee, Garena and SeaMoney.
Cambodia Bans Talc Powder Imports Over Asbestos
Cambodia has temporarily halted imports and distribution of talcum powder products after asbestos was discovered in several brands of baby powder.
Japan Donates Vehicles and Rescue Equipment to Help Flood-Stricken Laos
The Japanese government has provided vehicles to the Ministry of Labor and Social Welfare as part of efforts to tackle widespread flooding across the country.
Laos Government Affirms Commitment to Preventing Default
The Government of Laos has reiterated its pledge to avoid default, with relevant agencies being directed to take more proactive measures to address the country’s economic problems.
Realord Group Announces FY2022 Interim Results; Recorded Revenue increased by 31.0% YoY to HK$580 million
- Revenue increased by 31.0% to approximately HK$583.3 million.
- Profit Attribute to Owners of the Group increased by 8.3% to approximately HK$51.3 million
- The Latin America and Caribbean Segment recorded a segment result of approximately HK$576.2 million
- The Financial Services Segment recorded a segment result of approximately HK$17.0 million
- The Environmental Protection Segment recorded a segment result of approximately HK$12.0 million
- Basic earnings per share was 3.56 cents.
Financial Highlights:
For the 6 months ended 30 June | |||
HK$’000 | 2022 | 2021 | Change |
Revenue | 583,297 | 445,408 | +31.0% |
Gross profit | 137,783 | 132,439 | +4.0% |
Profit for the Period | 204,089 | 53,115 | +284.2% |
Profit attributable to owners | 51,275 | 47,356 | +8.3% |
Basic earnings per share (HK cents) | 3.56 | 3.29 | +8.1% |
HONG KONG SAR – Media OutReach – 26 August 2022 – Realord Group Holdings Limited (the “Company”, together with its subsidiaries, the “Group”, stock code: 1196) is pleased to present the consolidated results of the Group for the six months ended 30 June 2022 (“Period” or “1H2022”). During the Period, the Group recorded a total revenue of approximately HK$583.3 million, representing a year-on-year growth of 31.0%; Gross profit was HK$137.8 million, representing a year-on-year increase of 4.0%; Profit and Profit attributable to owners for the Period was HK$204.08 million and HK$51.27 million respectively, representing year-on-year increases of 284.2% and 8.1% respectively; Basic earnings per share for the Year was HK$3.56 cent.
Business Review, Outlook and Corporate Strategy
The principal activities of the Group during the Period included the Segments of Property, Financial Services, the Environmental Protection (“EP”), Motor Vehicle Parts (“MVP”), Commercial Printing, Hangtag, Department Store and the Latin America & Caribbean (“LAC”).
The LAC Segment
The Group owns a project (“Grenada Project”) comprising 3 lots of land with admeasurement 450 acres situated at the Mt. Hartman area in the parish of Saint George, Grenada. Grenada Project involves the development of a mixed property project consisting educational facilities, apartments for student, residential properties, hotel and resort facilities, commercial development and shopping facilities and in a longer plan university establishment(s) and related amenities.
Through a Citizenship by Investment Programme of Grenada (“CBI Programme”), the Group is authorised by Grenada Government to raise capital from investors of the Project for funding the construction and development costs. Qualified investors of the real properties will be granted permanent Grenadian citizenship and a passport. The revenue generated from consultancy services under CBI programmer was HK$3.3 million in 1H2022 and the segment profit of LAC Segment was approximately HK$576.2 million, due to a fair value gain on the investment properties in Grenada.
The Group is keen to leverage its experience in the Grenada Project to explore further investment opportunities around the Caribbean economic zone and Latin American region. The Group has further targeted to invest in four other Caribbean countries, namely Antigua and Barbuda, Saint Lucia, Saint Kitts and Nevis, and Dominica. The Group has identified four investment propositions to collaborate with the respective local governments to accelerate economic development of each country. These four areas include (i) the clean energy sector; (ii) the education sector; (iii) the tourism sector; and (iv) the retail sector
The Group is identifying capable and competent business partners with significant track record to participate in the projects. Subject to the planning and the feasibility studies of the projects as well as the requisite approval by the respective local government, it is expected that the Group would kick off the projects in the Designated Caribbean Countries and the Republic of Panama in the near future. To this end, the Group has established a management and marketing team with offices in Beijing, Shanghai, Shenzhen and Hong Kong and established a local sales network in Vietnam, and the U.S. to implement the marketing strategies formulated for promoting the citizenship investment programmes and investment opportunities of each of the aforesaid countries.
The Financial Services Segment
The Financial Services Segment generated a revenue of approximately HK$63.1 million in 1H2022, representing a slightly decrease of 5.0% from the previous year. The decrease in revenue of the Financial Services Segment was mainly resulted from the decrease in services provided to its customers, including placing services and underwriting services for certain initial public offering (“IPO”) projects. The aforesaid effect was partially offsetted by the margin interest income, margin financing services and interest from the money lending.
During the Period under Review, the segment recorded a segment profit of approximately HK$17.0 million. The segment profit was improved by decrease in commission expenses by approximately HK$2.3 million due to the decrease in placing services and decrease in provision for impairment losses on the loan receivables.
The Financial Services Segment will continuously develop various investment products to meet the market’s demand. At the same time, the Segment is also proactively preparing to launch dark pools and US stock trading systems; and expand the sales and business teams to support our business development. Therefore, the Segment is expected to achieve stable business growth in the second half of 2022.
The EP Segment
With the steady growth of copper price and continuing increased scale and established suppliers’ network of during 1H2022, the EP Segment generated revenue of approximately HK$356.1 million, representing an increase of approximately 38.7%. The segment profit for the EP Segment in 1H2022 was HK$12.0 million.
Looking forward, amidst the market uncertainties, the Group will continue to exercise extreme cautions in the operations of the EP Segment with a view to controlling operating costs, minimising the credit risk exposures, and expanding the customers base of the segments by strengthening their competitive edges among their competitors. The Group is looking into alternatives such as deploying additional operation points in Kyushu, Japan to meet the economy recovery after the COVID-19 pandemic for sustain growth of the EP business.
Mr. Bryan Lin Xiaohui, Chairman of Realord Group said, “Grenada project has now initially achieved results and the Group believes the promising prospects in Latin America and the Caribbean Region. Thus we will actively utilise the market synergy to fortify our leading position of the Group in the region, in order to maximise the return to our Shareholders and Investors.”
Hashtag: #RealordGroup
The issuer is solely responsible for the content of this announcement.
About Reaload Group Holdings Limited
Realord Group Holdings Limited (“Realord Group) is principally engaged in various segments including Property Investment, Financial Services (including corporate finance advisory, asset management, securities brokerage services, margin financing and money lending), Environmental Protection (mainly dismantling and trading of scrap materials), Distribution and Sale of Motor Vehicle Parts, Department Store. In recent years, the Group has commenced the Latin American & Caribbean Segment, in which is carrying out a development project in Grenada. The Project involves the development of a mixed property project consisting educational facilities, apartments for student, residential properties, hotel and resort facilities, commercial development and shopping facilities and in a longer plan university establishment(s) and related amenities. The Group plans to commence property development and investment business in the Republic of Panama.